PML risk stratification using anti-JCV antibody index and L-selectin
Background: Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD6...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2016-07, Vol.22 (8), p.1048-1060 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1060 |
|---|---|
| container_issue | 8 |
| container_start_page | 1048 |
| container_title | Multiple sclerosis |
| container_volume | 22 |
| creator | Schwab, Nicholas Schneider-Hohendorf, Tilman Pignolet, Béatrice Spadaro, Michela Görlich, Dennis Meinl, Ingrid Windhagen, Susanne Tackenberg, Björn Breuer, Johanna Cantó, Ester Kümpfel, Tania Hohlfeld, Reinhard Siffrin, Volker Luessi, Felix Posevitz-Fejfár, Anita Montalban, Xavier Meuth, Sven G Zipp, Frauke Gold, Ralf Du Pasquier, Renaud A Kleinschnitz, Christoph Jacobi, Annett Comabella, Manuel Bertolotto, Antonio Brassat, David Wiendl, Heinz |
| description | Background:
Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters.
Objective:
This study aimed at verifying and integrating both parameters into one algorithm for risk stratification.
Methods:
Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patients).
Results:
CD62L values correlate with JCV serostatus, as well as JCV index values. Low CD62L in natalizumab-treated patients was confirmed and validated as a biomarker for PML risk with the risk factor “CD62L low” increasing a patient’s relative risk 55-fold (p < 0.0001). Validation efforts established 86% sensitivity/91% specificity for CD62L and 100% sensitivity/59% specificity for JCV index as predictors of PML. Using both parameters identified 1.9% of natalizumab-treated patients in the reference center as the risk group.
Conclusions:
Both JCV index and CD62L have merit for risk stratification and share a potential biological relationship with implications for general PML etiology. A risk algorithm incorporating both biomarkers could strongly reduce PML incidence. |
| doi_str_mv | 10.1177/1352458515607651 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808664629</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458515607651</sage_id><sourcerecordid>1808664629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-2ba7747eed1b5d9db4095683d4c90330b173ba744f1fc780e02a625f5d2dcf3a3</originalsourceid><addsrcrecordid>eNqNkUtLw0AQxxdRrFbvniTgxUt09r05Sn1T0YN6DZvdTdmaJjWbgP32bm0VKQhe5sH85j_MDEJHGM4wlvIcU04YVxxzAVJwvIX2MJMyhUzCdoxjOV3WB2g_hCkASEn5LhoQwShRXO2hy6eHcdL68JaErtWdL72JtqmTPvh6kui68-n96PUrKBq7SHxt3UdMbTJOg6uc6Xx9gHZKXQV3uPZD9HJ99Ty6TcePN3eji3FqGIMuJYWWkknnLC64zWzBIONCUctMBpRCgSWNCGMlLo1U4IBoQXjJLbGmpJoO0elKd942770LXT7zwbiq0rVr-pBjBUoIJkj2H5RIKjCmET3ZQKdN39ZxkRxnkBGlMINIwYoybRNC68p83vqZbhc5hnz5jHzzGbHleC3cFzNnfxq-rx-BdAUEPXG_pv4l-An2zo5t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1909288140</pqid></control><display><type>article</type><title>PML risk stratification using anti-JCV antibody index and L-selectin</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Schwab, Nicholas ; Schneider-Hohendorf, Tilman ; Pignolet, Béatrice ; Spadaro, Michela ; Görlich, Dennis ; Meinl, Ingrid ; Windhagen, Susanne ; Tackenberg, Björn ; Breuer, Johanna ; Cantó, Ester ; Kümpfel, Tania ; Hohlfeld, Reinhard ; Siffrin, Volker ; Luessi, Felix ; Posevitz-Fejfár, Anita ; Montalban, Xavier ; Meuth, Sven G ; Zipp, Frauke ; Gold, Ralf ; Du Pasquier, Renaud A ; Kleinschnitz, Christoph ; Jacobi, Annett ; Comabella, Manuel ; Bertolotto, Antonio ; Brassat, David ; Wiendl, Heinz</creator><creatorcontrib>Schwab, Nicholas ; Schneider-Hohendorf, Tilman ; Pignolet, Béatrice ; Spadaro, Michela ; Görlich, Dennis ; Meinl, Ingrid ; Windhagen, Susanne ; Tackenberg, Björn ; Breuer, Johanna ; Cantó, Ester ; Kümpfel, Tania ; Hohlfeld, Reinhard ; Siffrin, Volker ; Luessi, Felix ; Posevitz-Fejfár, Anita ; Montalban, Xavier ; Meuth, Sven G ; Zipp, Frauke ; Gold, Ralf ; Du Pasquier, Renaud A ; Kleinschnitz, Christoph ; Jacobi, Annett ; Comabella, Manuel ; Bertolotto, Antonio ; Brassat, David ; Wiendl, Heinz</creatorcontrib><description>Background:
Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters.
Objective:
This study aimed at verifying and integrating both parameters into one algorithm for risk stratification.
Methods:
Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patients).
Results:
CD62L values correlate with JCV serostatus, as well as JCV index values. Low CD62L in natalizumab-treated patients was confirmed and validated as a biomarker for PML risk with the risk factor “CD62L low” increasing a patient’s relative risk 55-fold (p < 0.0001). Validation efforts established 86% sensitivity/91% specificity for CD62L and 100% sensitivity/59% specificity for JCV index as predictors of PML. Using both parameters identified 1.9% of natalizumab-treated patients in the reference center as the risk group.
Conclusions:
Both JCV index and CD62L have merit for risk stratification and share a potential biological relationship with implications for general PML etiology. A risk algorithm incorporating both biomarkers could strongly reduce PML incidence.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458515607651</identifier><identifier>PMID: 26432858</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Algorithms ; Antibodies, Viral - blood ; Biomarkers - blood ; Electrocardiography ; Encephalitis ; Etiology ; Europe ; Humans ; Immunocompromised Host ; Immunotherapy ; JC Virus - immunology ; L-selectin ; L-Selectin - blood ; Leukoencephalopathy ; Leukoencephalopathy, Progressive Multifocal - chemically induced ; Leukoencephalopathy, Progressive Multifocal - immunology ; Leukoencephalopathy, Progressive Multifocal - prevention & control ; Leukoencephalopathy, Progressive Multifocal - virology ; Monoclonal antibodies ; Multiple Sclerosis - blood ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - immunology ; Natalizumab - adverse effects ; Opportunistic Infections - chemically induced ; Opportunistic Infections - immunology ; Opportunistic Infections - virology ; Progressive multifocal leukoencephalopathy ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Serologic Tests ; Treatment Outcome ; Viral infections</subject><ispartof>Multiple sclerosis, 2016-07, Vol.22 (8), p.1048-1060</ispartof><rights>The Author(s), 2015</rights><rights>The Author(s), 2015.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-2ba7747eed1b5d9db4095683d4c90330b173ba744f1fc780e02a625f5d2dcf3a3</citedby><cites>FETCH-LOGICAL-c440t-2ba7747eed1b5d9db4095683d4c90330b173ba744f1fc780e02a625f5d2dcf3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458515607651$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458515607651$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,777,781,21800,27905,27906,43602,43603</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26432858$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schwab, Nicholas</creatorcontrib><creatorcontrib>Schneider-Hohendorf, Tilman</creatorcontrib><creatorcontrib>Pignolet, Béatrice</creatorcontrib><creatorcontrib>Spadaro, Michela</creatorcontrib><creatorcontrib>Görlich, Dennis</creatorcontrib><creatorcontrib>Meinl, Ingrid</creatorcontrib><creatorcontrib>Windhagen, Susanne</creatorcontrib><creatorcontrib>Tackenberg, Björn</creatorcontrib><creatorcontrib>Breuer, Johanna</creatorcontrib><creatorcontrib>Cantó, Ester</creatorcontrib><creatorcontrib>Kümpfel, Tania</creatorcontrib><creatorcontrib>Hohlfeld, Reinhard</creatorcontrib><creatorcontrib>Siffrin, Volker</creatorcontrib><creatorcontrib>Luessi, Felix</creatorcontrib><creatorcontrib>Posevitz-Fejfár, Anita</creatorcontrib><creatorcontrib>Montalban, Xavier</creatorcontrib><creatorcontrib>Meuth, Sven G</creatorcontrib><creatorcontrib>Zipp, Frauke</creatorcontrib><creatorcontrib>Gold, Ralf</creatorcontrib><creatorcontrib>Du Pasquier, Renaud A</creatorcontrib><creatorcontrib>Kleinschnitz, Christoph</creatorcontrib><creatorcontrib>Jacobi, Annett</creatorcontrib><creatorcontrib>Comabella, Manuel</creatorcontrib><creatorcontrib>Bertolotto, Antonio</creatorcontrib><creatorcontrib>Brassat, David</creatorcontrib><creatorcontrib>Wiendl, Heinz</creatorcontrib><title>PML risk stratification using anti-JCV antibody index and L-selectin</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Background:
Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters.
Objective:
This study aimed at verifying and integrating both parameters into one algorithm for risk stratification.
Methods:
Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patients).
Results:
CD62L values correlate with JCV serostatus, as well as JCV index values. Low CD62L in natalizumab-treated patients was confirmed and validated as a biomarker for PML risk with the risk factor “CD62L low” increasing a patient’s relative risk 55-fold (p < 0.0001). Validation efforts established 86% sensitivity/91% specificity for CD62L and 100% sensitivity/59% specificity for JCV index as predictors of PML. Using both parameters identified 1.9% of natalizumab-treated patients in the reference center as the risk group.
Conclusions:
Both JCV index and CD62L have merit for risk stratification and share a potential biological relationship with implications for general PML etiology. A risk algorithm incorporating both biomarkers could strongly reduce PML incidence.</description><subject>Algorithms</subject><subject>Antibodies, Viral - blood</subject><subject>Biomarkers - blood</subject><subject>Electrocardiography</subject><subject>Encephalitis</subject><subject>Etiology</subject><subject>Europe</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Immunotherapy</subject><subject>JC Virus - immunology</subject><subject>L-selectin</subject><subject>L-Selectin - blood</subject><subject>Leukoencephalopathy</subject><subject>Leukoencephalopathy, Progressive Multifocal - chemically induced</subject><subject>Leukoencephalopathy, Progressive Multifocal - immunology</subject><subject>Leukoencephalopathy, Progressive Multifocal - prevention & control</subject><subject>Leukoencephalopathy, Progressive Multifocal - virology</subject><subject>Monoclonal antibodies</subject><subject>Multiple Sclerosis - blood</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - immunology</subject><subject>Natalizumab - adverse effects</subject><subject>Opportunistic Infections - chemically induced</subject><subject>Opportunistic Infections - immunology</subject><subject>Opportunistic Infections - virology</subject><subject>Progressive multifocal leukoencephalopathy</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Serologic Tests</subject><subject>Treatment Outcome</subject><subject>Viral infections</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtLw0AQxxdRrFbvniTgxUt09r05Sn1T0YN6DZvdTdmaJjWbgP32bm0VKQhe5sH85j_MDEJHGM4wlvIcU04YVxxzAVJwvIX2MJMyhUzCdoxjOV3WB2g_hCkASEn5LhoQwShRXO2hy6eHcdL68JaErtWdL72JtqmTPvh6kui68-n96PUrKBq7SHxt3UdMbTJOg6uc6Xx9gHZKXQV3uPZD9HJ99Ty6TcePN3eji3FqGIMuJYWWkknnLC64zWzBIONCUctMBpRCgSWNCGMlLo1U4IBoQXjJLbGmpJoO0elKd942770LXT7zwbiq0rVr-pBjBUoIJkj2H5RIKjCmET3ZQKdN39ZxkRxnkBGlMINIwYoybRNC68p83vqZbhc5hnz5jHzzGbHleC3cFzNnfxq-rx-BdAUEPXG_pv4l-An2zo5t</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Schwab, Nicholas</creator><creator>Schneider-Hohendorf, Tilman</creator><creator>Pignolet, Béatrice</creator><creator>Spadaro, Michela</creator><creator>Görlich, Dennis</creator><creator>Meinl, Ingrid</creator><creator>Windhagen, Susanne</creator><creator>Tackenberg, Björn</creator><creator>Breuer, Johanna</creator><creator>Cantó, Ester</creator><creator>Kümpfel, Tania</creator><creator>Hohlfeld, Reinhard</creator><creator>Siffrin, Volker</creator><creator>Luessi, Felix</creator><creator>Posevitz-Fejfár, Anita</creator><creator>Montalban, Xavier</creator><creator>Meuth, Sven G</creator><creator>Zipp, Frauke</creator><creator>Gold, Ralf</creator><creator>Du Pasquier, Renaud A</creator><creator>Kleinschnitz, Christoph</creator><creator>Jacobi, Annett</creator><creator>Comabella, Manuel</creator><creator>Bertolotto, Antonio</creator><creator>Brassat, David</creator><creator>Wiendl, Heinz</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201607</creationdate><title>PML risk stratification using anti-JCV antibody index and L-selectin</title><author>Schwab, Nicholas ; Schneider-Hohendorf, Tilman ; Pignolet, Béatrice ; Spadaro, Michela ; Görlich, Dennis ; Meinl, Ingrid ; Windhagen, Susanne ; Tackenberg, Björn ; Breuer, Johanna ; Cantó, Ester ; Kümpfel, Tania ; Hohlfeld, Reinhard ; Siffrin, Volker ; Luessi, Felix ; Posevitz-Fejfár, Anita ; Montalban, Xavier ; Meuth, Sven G ; Zipp, Frauke ; Gold, Ralf ; Du Pasquier, Renaud A ; Kleinschnitz, Christoph ; Jacobi, Annett ; Comabella, Manuel ; Bertolotto, Antonio ; Brassat, David ; Wiendl, Heinz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-2ba7747eed1b5d9db4095683d4c90330b173ba744f1fc780e02a625f5d2dcf3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Algorithms</topic><topic>Antibodies, Viral - blood</topic><topic>Biomarkers - blood</topic><topic>Electrocardiography</topic><topic>Encephalitis</topic><topic>Etiology</topic><topic>Europe</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Immunotherapy</topic><topic>JC Virus - immunology</topic><topic>L-selectin</topic><topic>L-Selectin - blood</topic><topic>Leukoencephalopathy</topic><topic>Leukoencephalopathy, Progressive Multifocal - chemically induced</topic><topic>Leukoencephalopathy, Progressive Multifocal - immunology</topic><topic>Leukoencephalopathy, Progressive Multifocal - prevention & control</topic><topic>Leukoencephalopathy, Progressive Multifocal - virology</topic><topic>Monoclonal antibodies</topic><topic>Multiple Sclerosis - blood</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - immunology</topic><topic>Natalizumab - adverse effects</topic><topic>Opportunistic Infections - chemically induced</topic><topic>Opportunistic Infections - immunology</topic><topic>Opportunistic Infections - virology</topic><topic>Progressive multifocal leukoencephalopathy</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Serologic Tests</topic><topic>Treatment Outcome</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schwab, Nicholas</creatorcontrib><creatorcontrib>Schneider-Hohendorf, Tilman</creatorcontrib><creatorcontrib>Pignolet, Béatrice</creatorcontrib><creatorcontrib>Spadaro, Michela</creatorcontrib><creatorcontrib>Görlich, Dennis</creatorcontrib><creatorcontrib>Meinl, Ingrid</creatorcontrib><creatorcontrib>Windhagen, Susanne</creatorcontrib><creatorcontrib>Tackenberg, Björn</creatorcontrib><creatorcontrib>Breuer, Johanna</creatorcontrib><creatorcontrib>Cantó, Ester</creatorcontrib><creatorcontrib>Kümpfel, Tania</creatorcontrib><creatorcontrib>Hohlfeld, Reinhard</creatorcontrib><creatorcontrib>Siffrin, Volker</creatorcontrib><creatorcontrib>Luessi, Felix</creatorcontrib><creatorcontrib>Posevitz-Fejfár, Anita</creatorcontrib><creatorcontrib>Montalban, Xavier</creatorcontrib><creatorcontrib>Meuth, Sven G</creatorcontrib><creatorcontrib>Zipp, Frauke</creatorcontrib><creatorcontrib>Gold, Ralf</creatorcontrib><creatorcontrib>Du Pasquier, Renaud A</creatorcontrib><creatorcontrib>Kleinschnitz, Christoph</creatorcontrib><creatorcontrib>Jacobi, Annett</creatorcontrib><creatorcontrib>Comabella, Manuel</creatorcontrib><creatorcontrib>Bertolotto, Antonio</creatorcontrib><creatorcontrib>Brassat, David</creatorcontrib><creatorcontrib>Wiendl, Heinz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schwab, Nicholas</au><au>Schneider-Hohendorf, Tilman</au><au>Pignolet, Béatrice</au><au>Spadaro, Michela</au><au>Görlich, Dennis</au><au>Meinl, Ingrid</au><au>Windhagen, Susanne</au><au>Tackenberg, Björn</au><au>Breuer, Johanna</au><au>Cantó, Ester</au><au>Kümpfel, Tania</au><au>Hohlfeld, Reinhard</au><au>Siffrin, Volker</au><au>Luessi, Felix</au><au>Posevitz-Fejfár, Anita</au><au>Montalban, Xavier</au><au>Meuth, Sven G</au><au>Zipp, Frauke</au><au>Gold, Ralf</au><au>Du Pasquier, Renaud A</au><au>Kleinschnitz, Christoph</au><au>Jacobi, Annett</au><au>Comabella, Manuel</au><au>Bertolotto, Antonio</au><au>Brassat, David</au><au>Wiendl, Heinz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PML risk stratification using anti-JCV antibody index and L-selectin</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2016-07</date><risdate>2016</risdate><volume>22</volume><issue>8</issue><spage>1048</spage><epage>1060</epage><pages>1048-1060</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><abstract>Background:
Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters.
Objective:
This study aimed at verifying and integrating both parameters into one algorithm for risk stratification.
Methods:
Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patients).
Results:
CD62L values correlate with JCV serostatus, as well as JCV index values. Low CD62L in natalizumab-treated patients was confirmed and validated as a biomarker for PML risk with the risk factor “CD62L low” increasing a patient’s relative risk 55-fold (p < 0.0001). Validation efforts established 86% sensitivity/91% specificity for CD62L and 100% sensitivity/59% specificity for JCV index as predictors of PML. Using both parameters identified 1.9% of natalizumab-treated patients in the reference center as the risk group.
Conclusions:
Both JCV index and CD62L have merit for risk stratification and share a potential biological relationship with implications for general PML etiology. A risk algorithm incorporating both biomarkers could strongly reduce PML incidence.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>26432858</pmid><doi>10.1177/1352458515607651</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2016-07, Vol.22 (8), p.1048-1060 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1808664629 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Algorithms Antibodies, Viral - blood Biomarkers - blood Electrocardiography Encephalitis Etiology Europe Humans Immunocompromised Host Immunotherapy JC Virus - immunology L-selectin L-Selectin - blood Leukoencephalopathy Leukoencephalopathy, Progressive Multifocal - chemically induced Leukoencephalopathy, Progressive Multifocal - immunology Leukoencephalopathy, Progressive Multifocal - prevention & control Leukoencephalopathy, Progressive Multifocal - virology Monoclonal antibodies Multiple Sclerosis - blood Multiple Sclerosis - diagnosis Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Natalizumab - adverse effects Opportunistic Infections - chemically induced Opportunistic Infections - immunology Opportunistic Infections - virology Progressive multifocal leukoencephalopathy Retrospective Studies Risk Assessment Risk Factors Serologic Tests Treatment Outcome Viral infections |
| title | PML risk stratification using anti-JCV antibody index and L-selectin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A48%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PML%20risk%20stratification%20using%20anti-JCV%20antibody%20index%20and%20L-selectin&rft.jtitle=Multiple%20sclerosis&rft.au=Schwab,%20Nicholas&rft.date=2016-07&rft.volume=22&rft.issue=8&rft.spage=1048&rft.epage=1060&rft.pages=1048-1060&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/1352458515607651&rft_dat=%3Cproquest_cross%3E1808664629%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1909288140&rft_id=info:pmid/26432858&rft_sage_id=10.1177_1352458515607651&rfr_iscdi=true |